Since we launched our first IVD test kit in 1966 our products have consistently been recognized by the market for their excellence.
We have carried out a number of successful acquisitions of best-in-class IVD companies over the years (e.g. Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010).
This has further reinforced the know-how in our group and bolstered our capacity to innovate, develop, produce and deliver products of only the highest quality.
Products by diseases and disorders:
News & EventsView all news & upcoming events
Fujirebio Europe enters an agreement with ADx NeuroSciences for the commercialization of novel biomarkers
Fujirebio Europe announces CE marking of the fully automated Lumipulse® G SARS-CoV-2 antigen assay and the rapid antigen device ESPLINE® SARS-CoV-2
Fujirebio Europe launches the Lumipulse® G Aldosterone and Renin assays for fully automated quantitative determination of aldosterone and active renin
iAMP COVID-19 Detection kit, a molecular SARS-CoV-2 detection assay distributed by Fujirebio Europe, is now CE marked
Fujirebio Europe launches the automated Lumipulse® G SCC assay for the quantitative measurement of squamous cell carcinoma antigen
Fujirebio Europe launches iAMP COVID-19, a new molecular detection assay that eliminates the need for RNA extraction
Healthcare for You.
With our deep involvement in human health, we aim to be a group that contributes to the development of healthcare through trust and innovation.
What we hold dear is the starting point for the creation of a prosperous future.
That is, the health of each and every person.
Because we have been watching over people's health for many decades, we are able to change the future of medical care and create new possibilities in healthcare.
We will continue the challenge to deliver optimal healthcare to each individual.
We will move forward, unceasingly.
Healthcare for You.
For your health, for your future happiness.
A global partner of choice
Today, we sell our products in more than 100 countries worldwide.
We have offices in the United States, Latin America, Europe and Asia, and are supported by an international distribution network and leading OEMs.
Our proven commitment to manufacturing quality has earned us a strong reputation with our direct customers, and global partners at leading diagnostic companies.
Several fully automated and CLEIA-based LUMIPULSE G1200 systems from Fujirebio are right now performing fast, high sensitivity SARS CoV-2 antigen...
Aug 26, 2020
It has been estimated that in 2020, about 21,750 women in the US will receive a new ovarian cancer diagnosis and about 13,940 women will die from this...
Jul 29, 2020
Our own Rebecca Millecamps, Marketing Manager at Fujirebio, was interviewed for the podcast series 'Molecules, microbes and multiomics' about the...
Jun 22, 2020